BMPR2 and pulmonary arterial hypertension: A study conducted by Long et al. [129] reported the beneficial effects of BMP9 administration in heterozygous BMPR2 knockout mice, suggesting that compensating for BMPR2 haploinsufficiency by increasing dose of the ligand might constitute a targeted therapy for human PAH [129].